Teva Pharmaceutical received FDA approval for its Abbreviated New Drug Application (ANDA 202718) on December 29, 2014, enabling the generic launch of an unnamed drug candidate. This approval marks a significant step forward for the company, influencing its market share dynamics and competitive landscape within the relevant therapeutic category.